Zambon, Alberto

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsBody Composition Measurement Techniques

Cited by 1,966

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology

Cardiovascular Disease and AdiposityDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,603

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 688

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 463

Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression: Hepatic Lipase–Mediated Changes in LDL Density

Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 263

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 260

Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies

Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology

Dementia and Cognitive Impairment ResearchLipoproteins and Cardiovascular Health

Cited by 197

Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender and diet.

Deeb, S. S., Zambon, A., Carr, M. C., Ayyobi, A. F., & Brunzell, J. D. (2003) · Journal of Lipid Research

Lipid metabolism and disordersParaoxonase enzyme and polymorphisms

Cited by 193

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B

Capell, W. H., Zambon, A., Austin, M. A., Brunzell, J. D., & Hokanson, J. E. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 95

Non-pharmacological control of plasma cholesterol levels

Poli, A., Marangoni, F., Paoletti, R., Mannarino, E., Lupattelli, G., Notarbartolo, A., Aureli, P., Bernini, F., Cicero, A., Gaddi, A., et al. (2008) · Nutrition, Metabolism and Cardiovascular Diseases

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 63

Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: Do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials

Casula, M., Olmastroni, E., Gazzotti, M., Galimberti, F., Zambon, A., & Catapano, A. L. (2020) · Pharmacological Research

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 54

Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: a retrospective cohort study based on the AIFA monitoring registries

Arca, M., Celant, S., Olimpieri, P. P., Colatrella, A., Tomassini, L., D'Erasmo, L., Averna, M., Zambon, A., Catapano, A. L., & Russo, P. (2023) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 35

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies

Cicero, A. F. G., Fogacci, F., Zambon, A., Toth, P. P., & Borghi, C. (2022) · American Heart Journal Plus: Cardiology Research and Practice

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 34

Lessons from PROMINENT and prospects for pemafibrate

Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLiver Disease Diagnosis and Treatment

Cited by 16

Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry

D’Erasmo, L., Tramontano, D., Di Costanzo, A., Casula, M., Galimberti, F., Baratta, F., Cefalù, A. B., Tarugi, P. M., Calandra, S., Zambon, A., et al. (2025) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 9

Fibrates : Do They Still Have a Role in Therapy in 2025?

Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 4